TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04424004

Intervention type: OTHER
Intervention: COVID-19 PCR and serology testing
Description: 1. PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~2. Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months.
Study: NCT00053222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study: NCT04516824

Intervention type: PROCEDURE
Intervention: Orthopaedic Surgical Procedures
Description: Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
Study: NCT02870257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening protocol with progressive load
Description: Strengthening protocol for scapular and shoulder muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening protocol without progressive load
Description: Strengthening protocol for scapular and shoulder muscles
Study: NCT02855645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichosanthes root
Description: Trichosanthes root at a rate of 1.5 g two times per day for 84 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
Study: NCT01646567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP-141C
Description: Topical Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to SHP-141C
Description: Placebo Topical Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate
Description: Topical cream, 0.02%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Description: Topical cream, 0.005%
Study: NCT01304472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 10mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 150mg per day
Study: NCT02125630

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery to primary tumor

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery to primary tumor

Intervention type: DRUG
Intervention: Systemic therapy
Description: Systemic therapy based on tumor phenotype

Intervention type: DRUG
Intervention: Systemic therapy
Description: Systemic therapy based on tumor phenotype
Study: NCT01024660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 5 mg capsule, orally, once daily, first 14 days of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10 mg, orally, once daily, for remaining 70 days of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Aricept
Description: Placebo capsule, orally, 84 days of treatment
Study: NCT04509401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B 6 with Magnesium
Description: Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of vitamin B6 and magnesium
Description: Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
Study: NCT03158090

Intervention type: PROCEDURE
Intervention: Transnasal butterfly surgery
Description: The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.

Intervention type: DRUG
Intervention: sandostatin
Description: The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient

Intervention type: RADIATION
Intervention: radiotherapy
Description: The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
Study: NCT00962468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD evidence based care pathway
Description: A care pathways, as complex intervention, will be implemented.
Study: NCT04645966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 (60-µg Dose)
Description: Trumenba (half dose) - Meningococcal Group B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 (60-µg Dose)
Description: Trumenba (half dose) - Meningococcal Group B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 (120-µg Dose)
Description: Trumenba - Meningococcal Group B vaccine
Study: NCT04356872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: immune check point inhibitor, 200mg, iv, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: ADM, 60mg/m2, iv, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: IFO, 1.8 g/m2/d, d1-5
Study: NCT02130752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monopolar electrocautery
Description: During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Description: During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
Study: NCT03024710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention cluster
Description: The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
Study: NCT02959697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcut. + Subconj. Xylocaine
Description: Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Subcut. + Sham Subconj. Injection
Description: Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Blepharoptosis Repair
Description: Patients will undergo blepharoptosis repair using an anterior approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blepharoptosis Repair
Description: Patients will undergo blepharoptosis repair using an anterior approach.
Study: NCT05810389

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Application methods of delivery of topical fluoride

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Application methods of delivery of topical fluoride
Study: NCT04645966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero
Description: Bexsero - Meningococcal Group B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero
Description: Bexsero - Meningococcal Group B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero
Description: Bexsero - Meningococcal Group B vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Liquid Paracetamol (PLP)
Description: PLP administration during primary vaccinations 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Liquid Paracetamol (PLP)
Description: PLP administration during primary vaccinations 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Liquid Paracetamol (PLP)
Description: PLP administration during primary vaccinations 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Liquid Paracetamol (PLP)
Description: PLP administration during primary vaccinations 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Liquid Paracetamol (PLP)
Description: PLP administration during primary vaccinations 1 and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Nimenrix - Meningococcal Group A, C, W and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Nimenrix - Meningococcal Group A, C, W and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Nimenrix - Meningococcal Group A, C, W and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Nimenrix - Meningococcal Group A, C, W and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Nimenrix - Meningococcal Group A, C, W and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Nimenrix - Meningococcal Group A, C, W and Y vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline
Study: NCT04599062

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
Study: NCT04430179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Description: 300 mg every other week for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active drug
Study: NCT02411448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered orally.
Study: NCT05810389

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Application methods of delivery of topical fluoride
Study: NCT01966653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrofurantoin
Description: nitrofurantoin 100 mg po tid for 5 days
Study: NCT02411448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally.
Study: NCT03309033

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT01966653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosfomycin
Description: fosfomycin 3g po single dose
Study: NCT05209958

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil Lynphosite ratio
Description: The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil Lynphosite ratio
Description: The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
Study: NCT01144091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxyphylline
Description: pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
Study: NCT04645966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scheduled Liquid Paracetamol (SLP)
Description: SLP administration after primary vaccinations 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scheduled Liquid Paracetamol (SLP)
Description: SLP administration after primary vaccinations 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scheduled Liquid Paracetamol (SLP)
Description: SLP administration after primary vaccinations 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Liquid Paracetamol (TLP)
Description: TLP administration after primary vaccinations 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Liquid Paracetamol (TLP)
Description: TLP administration after primary vaccinations 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Liquid Paracetamol (TLP)
Description: TLP administration after primary vaccinations 1 and 2
Study: NCT02445274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior lens capsule was reserved
Description: The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
Study: NCT03748030

Intervention type: RADIATION
Intervention: Confirmed Left-Sided Breast Cancer
Description: Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
Study: NCT03433898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion
Study: NCT02875015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: 20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride and Lidocaine
Description: Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suburethral Sling
Description: A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suburethral Sling
Description: A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
Study: NCT01878461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101
Study: NCT04642651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
Study: NCT01316302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pristiq
Description: Flexible dose, 50-100mg QD, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, taken QD for 12 weeks.
Study: NCT03891030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist Based Box system intervention
Description: The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
Study: NCT04391530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotional freedom technique, breathing therapy
Description: emotional freedom technique, breathing therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotional freedom technique, breathing therapy
Description: emotional freedom technique, breathing therapy
Study: NCT01490983

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no access to eMedonline
Description: patients will be followed for 3 months but will not use eMedonline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMedonline access
Description: patients will be given access to eMedonline use for 3 months
Study: NCT01144091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxiphylline
Description: pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
Study: NCT01449097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Blockade
Description: US-guided Adductor-Canal-blockade with Ropivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The femoral nerve block
Description: US-guided femoral nerve block with ropivacaine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: US-guided Adductor-Canal-Blockade/femoral nerve block with saline
Study: NCT01144091

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
Study: NCT03052868

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Assessment
Description: Cognitive testing session
Study: NCT05396261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Film forming silicone gel (7-0940)
Description: Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.
Study: NCT00142233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ANTOX (vers.)1.2
Description: 300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: 15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo ANTOX (vers)1.2
Description: Placebo ANTOX (vers)1.2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ANTOX (vers)1.2
Description: Placebo ANTOX (vers)1.2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Magnesiocard (2.5 mmol)
Description: Placebo Magnesiocard (2.5 mmol)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Magnesiocard (2.5 mmol)
Description: Placebo Magnesiocard (2.5 mmol)
Study: NCT01119508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Induction Phase, 200 mg/m\^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.